Artículo

Dolosigranulum pigrum modulates immunity against SARS-CoV-2 in respiratory epithelial cells

Islam, Md Aminul Icon; Albarracín, Leonardo Miguel Icon; Melnikov, Vyacheslav Icon; Andrade, Bruno G. N. ; Cuadrat, Rafael R. C. ; Kitazawa, Haruki Icon; Villena, Julio Cesar Icon

Otros responsables

Fecha

05/2021

Editorial

MDPI AG

Revista

Pathogens

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

2076-0817

eISSN

2076-0817

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

In a previous work, we demonstrated that nasally administered Dolosigranulum pigrum 040417 beneficially modulated the respiratory innate immune response triggered by the activation of Toll-like receptor 3 (TLR3) and improved protection against Respiratory Syncytial Virus (RSV) in mice. In this work, we aimed to evaluate the immunomodulatory effects of D. pigrum 040417 in human respiratory epithelial cells and the potential ability of this immunobiotic bacterium to in-crease the protection against Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The respiratory commensal bacterium D. pigrum 040417 differentially modulated the production of IFN-β, IL-6, CXCL8, CCL5 and CXCL10 in the culture supernatants of Calu-3 cells stimulated with poly(I:C) or challenged with SARS-CoV-2. The differential cytokine profile induced by the 040417 strain was associated with a significant reduction in viral replication and cellular damage after coronavirus infection. Of note, D. pigrum 030918 was not able to modify the resistance of Calu-3 cells to SARS-CoV-2 infection, indicating a strain-specific immunomodulatory effect for respiratory commensal bacteria. The findings of this work improve our understanding of the immunological mechanisms involved in the modulation of respiratory immunity induced by respiratory commensal bacteria, by demonstrating their specific effect on respiratory epithelial cells. In addition, the results suggest that particular strains such as D. pigrum 040417 could be used as a promising alternative for combating SARS-CoV-2 and reducing the severity of COVID-19.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by